Roche puts CMOS sensors into sequencing race

Roche has launched AXELIOS 1, a next-generation sequencing platform built around sequencing by expansion technology, reusable CMOS sensor modules, and near real-time analysis.

The system is initially available for research use only and is not approved for diagnostic procedures. Roche is targeting whole-genome sequencing, whole-exome sequencing, RNA sequencing, and other research workflows, with early applications covering single-cell RNA, spatial biology, methylation, oncology, genetics, and infectious disease research.

AXELIOS 1 uses SBX chemistry to convert DNA or RNA into expanded surrogate polymers known as Xpandomers. These carry sequence information into higher signal-to-noise reporters that can be threaded through nanopores and read using a reusable high-throughput CMOS sensor module. A dedicated analysis module then supports rapid base calling and downstream processing.

Roche is presenting the platform as a system for both smaller research projects and larger studies involving thousands of samples. The architecture is designed to support same-day whole-genome sequencing workflows, with read lengths of up to around 1500bp under suitable sample and library preparation conditions.

The launch places semiconductor sensing deeper inside life-science instrumentation. Sequencing systems are usually discussed through chemistry, biology, or clinical research, yet the underlying hardware now depends heavily on sensor design, low-noise measurement, embedded control, fluidics, thermal behaviour, data movement, and software pipelines. The CMOS module is not an incidental component; it influences throughput, signal quality, operating economics, and the ability to scale the platform across different research workloads.

Medical electronics manufacturing has been under renewed scrutiny as supply continuity, compliance, and production transfer become harder to manage across regulated supply chains. A recent analysis of resilience in medical device manufacturing looked at the shift from cost-led outsourcing towards strategies built around continuity, documentation, and regulatory alignment. AXELIOS 1 sits further upstream in research instrumentation, but it has to meet the same broader disciplines around component supply, build consistency, serviceability, and long-term support.

Reusable CMOS sensor modules also change the economics of the sequencing platform. Consumables remain central to sequencing workflows, but durable sensor hardware can affect cost per run, maintenance planning, calibration, and instrument utilisation. The engineering challenge is to preserve sensitivity and repeatability across repeated use, while keeping sample preparation and data analysis efficient enough for practical laboratory deployment.

Competition in sequencing is not only a contest over raw read length or machine price. Laboratories assess platform stability, software maturity, data quality, compatibility with established workflows, operating cost, service support, and the confidence that results can be reproduced across sites and studies. A new architecture must therefore prove itself through reliability as much as headline performance.

The broader direction is clear across medical instrumentation. Imaging, sequencing, diagnostic automation, and point-of-care platforms are absorbing semiconductor sensing and compute at a faster rate. Instruments that once relied on discrete electronics and separate analysis stages are becoming tightly integrated systems where sensor output, local processing, cloud-linked tools, and workflow software operate together.

AXELIOS 1 adds Roche to a sequencing market where hardware architecture is again central to competitive differentiation. The platform’s commercial performance will depend on adoption by research laboratories, but its technical interest lies in the way biology, CMOS sensing, nanopores, and data analysis have been pulled into a single instrument architecture.